Printer Friendly

FOREST LABORATORIES ANNOUNCES APPROVAL OF FLUMADINE, A NEW DRUG FOR THE PREVENTION AND TREATMENT OF INFLUENZA A

 NEW YORK, Sept. 20 /PRNewswire/ -- Forest Laboratories, Inc. (AMEX: FRX), an international pharmaceutical manufacturer and marketer, announced today that it had received U.S. marketing approval for its new antiviral drug Flumadine(R) (rimantadine HCL). Flumadine was approved for both the prophylaxis and treatment of Influenza A, a common type of flu which affects millions of patients in the United States each year.
 Howard Solomon, president of Forest, stated that: "We are very pleased to have received approval of Flumadine in time for the 1993-1994 influenza season. The Centers for Disease Control and Prevention anticipates the possibility that a new variant of the A/Beijing type flu may be prevalent this season. Flumadine is indicated for all types of Influenza A, including this new variant. Shipments to wholesalers will commence in September and our sales force will begin detailing the product in a primary position immediately thereafter."
 -0- 9/20/93
 /CONTACT: Kenneth E. Goodman, vice president-finance of Forest, 212-421-7850/
 (FRX)


CO: Forest Laboratories, Inc. ST: New York IN: MTC SU: PDT

GK-LD -- NY006 -- 3478 09/20/93 08:45 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 20, 1993
Words:181
Previous Article:DONALDSON COMPANY ANNOUNCES RECORD FOURTH-QUARTER AND FISCAL 1993 RESULTS
Next Article:CONSILIUM ADDS RAW MATERIALS MANAGEMENT FUNCTIONALITY TO FLOWSTREAM
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters